NATERA INC. news, videos and press releases
For more news please use our advanced search feature.
NATERA INC. - More news...
NATERA INC. - More news...
- Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
- Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
- Natera Reports Fourth Quarter and Full Year 2024 Financial Results
- Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
- Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
- NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
- Natera Announces National Commercial Coverage for its Fetal RhD NIPT
- Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
- Natera to Present New Data at the 2025 ASCO GI Symposium
- Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
- Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
- Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
- Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
- Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
- Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
- Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
- Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
- Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
- Natera Issues Statement on Guardant Health Litigation
- Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
- Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
- Natera Reports Third Quarter 2024 Financial Results
- Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
- NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
- Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
- Natera Reports Second Quarter 2023 Financial Results
- Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
- Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
- Natera to Report its Second Quarter 2023 Results on August 3rd
